
Rahul Banerjee: DREAMM-7 with Belantamab Mafodotin in R/R Multiple Myeloma
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, shared a post on X about an article published in The Lancet Oncology by Vania Hungria et al:
“Just in time for ODAC, DREAMM-7 OS with belantamab in The Lancet Oncology by Vania Hungria et al.
Look at those survival curves! They estimate mOS of 7 years (!) with Bela-Vd based on modeling even in R/R myeloma. No T-cell collection, no CRS risk – great for patients around the word.
Question #1 for MM.
ODAC is whether we know optimal biological dosing schema for bela-maf to efficacy and toxicity. We don’t yet – but future trials and RW evidence will help us find out!
ASCO Daily News predictions by Doris Hansen and me.”
Title: Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Authors: Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt, Albert Oriol Rocafiguera, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalinska, María-Victoria Mateos
More posts featuring Rahul Banerjee on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023